Please ensure Javascript is enabled for purposes of website accessibility
Taylor Carmichael

Taylor Carmichael

TMFSaintCroix

Taylor Carmichael is a former attorney and filmmaker. He's the author of a line of murder mysteries, including Whodidit in the Supreme Court? and Whodidit With a Senator? The majority of what he knows about stocks he learned right here at the Motley Fool.

Recent articles

GettyImages-999958684

Takeda Pharmaceutical Announces a Plasma-Derived Coronavirus Therapy

Plasma-derived therapies have proven effective in the treatment of severe acute viral respiratory infections.


GettyImages-1201312636

Vir Biotechnology and Alnylam Join the Fight Against COVID-19

The two biotechs are expanding their existing collaboration with the goal of developing an antiviral treatment for the novel coronavirus.


GettyImages-800433994

3 Small-Caps That Are Soaring Because of Coronavirus Panic

Some of the top stocks in 2020 are the companies that are fighting the coronavirus.


GettyImages-1201634413

Vir Biotechnology and WuXi Biologics to Collaborate on COVID-19 Treatment

News that the two biotechs are working together on monoclonal antibody treatments for the coronavirus has excited investors.


GettyImages-1150036618

Ionis Pharmaceuticals' Revenues Rose 85% in 2019

The biotechnology company's license fees increased almost 400% to $490 million.

GettyImages-1205778458

U.S. Health Official Warns: COVID-19 Will Hit the United States

Americans should prepare for the possibility that their lives will be disrupted due to the pandemic, says the CDC's Nancy Messonnier.


GettyImages-1137739670

Intercept Pharmaceuticals Reports 40% Revenue Growth for 2019

The company's lead drug, Ocaliva, brought in $249.6 million last year.


GettyImages-1162351765

These 2 Stocks Could Be 2020's Best Profit Opportunities

How do we find the top stock of 2020? The best performers in 2019 offer some clues.


GettyImages-1182014619

A Plan to Use Blockchain to Stop Counterfeit Drugs Moves Forward

A host of major healthcare companies and drug retailers are collaborating on a system to combat fake drugs.


GettyImages-1164242290

Anika Therapeutics Beats Revenue and Earnings Estimates

A recent acquisition and a new product launch held back earnings, but should be beneficial over the long term.

GettyImages-1135068422

3 High-Growth Stocks Whose Gains Are Just Getting Started

These young companies have already delivered big returns for their shareholders, and there's every reason to expect more to come.


GettyImages-1166057429

Vir Bio Identifies 2 Antibodies That Might Stop Coronavirus

Antibody-based treatments can be used both to protect people from infection and to treat those already affected.


GettyImages-508496956

Ionis Receives Orphan Drug Designation From EMA

The company is advancing a new treatment for people with Alexander disease.


GettyImages-945241580

Myriad Genetics CEO Mark Capone Resigns

The molecular diagnostics company also delivered an earnings miss, and its stock plunged.


GettyImages-904268290

Alnylam Beats Revenue Estimates, but Misses on Earnings

Shares of the genetic disease specialist were essentially flat in late afternoon trading.

GettyImages-840206400

Abiomed Crushed Its Earnings Estimates, but the Market Wasn't Impressed

The medical device maker's stock dropped 9%, then recovered.


GettyImages-1127257348

3 Top Small-Cap Stocks to Buy in February

An insurance-shopping portal, a U.K. software company, and a Brazilian medical school operator all have potential for outsize returns.


GettyImages-1140748326

Why Did Karuna Therapeutics Pop 26% in January?

The volatile biotech has been up and down since its massive gain back in November.


GettyImages-1042024608

2 Top Healthcare Stocks to Buy Right Now

These two biotechs have major drugs that should be hitting the market soon.


download

Why Sea Stock Was Up 12.5% in January

The Singapore internet giant might be entering the banking business.